Clinical Evidence: How Wegovy And Mounjaro Compare For Weight Loss
Is Wegovy The Same As Mounjaro? Understanding The Key Differences
Wegovy and Mounjaro are not the same medication, though both are prescription-only medicines licensed for weight management in the UK. Wegovy contains semaglutide, which acts as a GLP-1 receptor agonist, mimicking a natural hormone that promotes feelings of fullness. Mounjaro contains tirzepatide, which works as a dual agonist targeting both GIP and GLP-1 receptors, offering a slightly different mechanism of action. Both require clinical assessment and are designed to be used alongside lifestyle modifications for optimal weight loss results.
The distinction between these medications is important for patients seeking the most appropriate treatment option. Wegovy follows a structured dose escalation schedule from 0.25mg to a maintenance dose of 2.4mg over 16 weeks, whilst Mounjaro has its own dosing protocol. Both medications are manufactured by different companies – Wegovy by Novo Nordisk and Mounjaro by Eli Lilly – and have undergone separate clinical development programmes to demonstrate their safety and efficacy profiles.
Weight Loss Results: Wegovy Vs Mounjaro Pricing And Value
At EverydayMeds, Wegovy pricing starts from £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our bundle options provide convenient multi-month supplies, such as the Intro Trio (0.25mg, 0.5mg, and 1mg) for £299.99, ensuring patients can maintain their treatment schedule without interruption. New customers can apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices.
When comparing is Wegovy the same as Mounjaro from a cost perspective, both medications represent significant investments in long-term weight management. Our 2-pen bundles, such as the Progress Duo (0.5mg and 1mg) for £189.99, offer the convenience of fewer orders and Reliable Supply continuity. The Ultimate Stability Trio provides three months of 2.4mg maintenance supply for £649.99, supporting patients who have reached their target maintenance dose with reliable treatment access.
Clinical Evidence: STEP Trial Results For Wegovy Weight Loss
The landmark STEP clinical trial programme, published by Wilding et al. in the New England Journal of Medicine (2021), demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo. STEP 3 showed even higher results of around 16% when combined with intensive behavioural therapy, whilst STEP 5 confirmed sustained weight loss of approximately 15.2% at two years.
Most significantly for UK patients, the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events among participants taking semaglutide. These results contributed to NICE recommendation TA875, which supports Wegovy use within specialist weight management programmes, highlighting the distinction when patients ask is Wegovy the same as Mounjaro in terms of evidence base.
How Wegovy Works: GLP-1 Mechanism For Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally released by the intestine after eating. This mechanism reduces appetite by acting on appetite centres in the brain, promoting feelings of fullness after smaller meals, and may help reduce food cravings throughout the day. The once-weekly injection delivered via FlexTouch pen provides consistent medication levels, supporting sustained appetite control between doses. Unlike rapid-acting appetite suppressants, Wegovy's mechanism supports gradual, sustainable weight management when combined with lifestyle modifications. The medication's effect on gastric emptying also contributes to prolonged satiety, helping patients maintain reduced-calorie diets more comfortably.
Ordering Process: Assessment To Delivery At EverydayMeds
Our streamlined process begins with a 3-minute online clinical assessment covering medical history, current medications, and weight management goals to ensure Wegovy suitability. Qualified prescribers review each application within 3 working days (express 24-hour service available), ensuring clinical safety and regulatory compliance with MHRA guidelines. Once approved, medications are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity from our GPhC-registered pharmacy. All Wegovy pens arrive in pharmaceutical-grade packaging with clear storage instructions and injection guidance materials. Patients receive SMS tracking updates and can access our clinical support team throughout their treatment journey for ongoing assistance.
Storage And Practical Considerations: Wegovy Vs Mounjaro Differences
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable for up to 6 weeks at room temperature below 30°C once removed from refrigeration, versus just 21 days for Mounjaro. Before first use, Wegovy should be stored in the refrigerator at 2-8°C, making it suitable for travel and reducing the inconvenience of maintaining cold storage during short trips. The FlexTouch pen delivery system requires no mixing or preparation, with clear dose escalation from 0.25mg through to 2.4mg maintenance over 16 weeks. Patients cannot skip doses or accelerate the escalation schedule, as this increases the risk of gastrointestinal side effects and reduces treatment tolerability. This structured approach differentiates Wegovy's dosing protocol when patients research is Wegovy the same as Mounjaro for practical usage.
UK Weight Loss Results: Real-World Evidence Vs Clinical Trials
When UK patients ask is Wegovy the same as Mounjaro regarding real-world effectiveness, it's important to understand that both medications have shown substantial weight loss results in their respective clinical programmes. Real-world evidence studies in UK populations have generally confirmed clinical trial findings, with patients achieving meaningful weight loss when combining medication with dietary changes and increased physical activity. The key difference lies in individual response variability – some patients may respond better to Wegovy's GLP-1-only mechanism, whilst others might benefit from Mounjaro's dual receptor approach.
Success rates in UK clinical practice align closely with trial data, though individual results vary based on baseline BMI, comorbidities, and adherence to lifestyle modifications. Both medications require long-term commitment, as STEP 1 extension data showed patients regained approximately two-thirds of lost weight within one year of discontinuation, emphasising that weight management represents an ongoing journey rather than a temporary intervention.
Making Your Choice: Both Available From EverydayMeds
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which medication aligns best with your individual medical profile and weight management goals. Our clinical team considers factors including medical history, current medications, lifestyle preferences, and storage requirements when recommending treatment options. The question of is Wegovy the same as Mounjaro ultimately comes down to choosing the most appropriate mechanism and dosing schedule for your circumstances, supported by our comprehensive clinical assessment process.
Start your weight management journey today by completing our 3-minute online assessment, with new customers using code FIRST40 and returning patients applying DOSE25 at checkout. Our GPhC-registered pharmacy #9012878 ensures you receive genuine, MHRA-approved medications with full clinical support throughout your treatment. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment and discover which prescription-only weight management solution may be right for you. Remember that successful weight management requires combining medication with sustainable dietary changes and regular physical activity for optimal results.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
